Biospecifics - InvestorRoom http://investors.biospecifics.com/ BioSpecifics Technologies Corp. Appoints Ron Law, Ph.D, J.D., as Senior Vice President of Business Development http://investors.biospecifics.com/2018-11-15-BioSpecifics-Technologies-Corp-Appoints-Ron-Law-Ph-D-J-D-as-Senior-Vice-President-of-Business-Development Thu, 15 Nov 2018 16:30:00 -0500 http://investors.biospecifics.com/2018-11-15-BioSpecifics-Technologies-Corp-Appoints-Ron-Law-Ph-D-J-D-as-Senior-Vice-President-of-Business-Development BioSpecifics Technologies Corp. Reports Third Quarter 2018 Financial Results http://investors.biospecifics.com/2018-11-09-BioSpecifics-Technologies-Corp-Reports-Third-Quarter-2018-Financial-Results - Positive Phase 3 data from both RELEASE-1 and RELEASE-2 trials of CCH for the treatment of cellulite recently reported - Fri, 09 Nov 2018 08:01:00 -0500 http://investors.biospecifics.com/2018-11-09-BioSpecifics-Technologies-Corp-Reports-Third-Quarter-2018-Financial-Results BioSpecifics Technologies Corp. Announces Positive Topline Results from Phase 1 Study of CCH for the Treatment of Uterine Fibroids http://investors.biospecifics.com/2018-10-31-BioSpecifics-Technologies-Corp-Announces-Positive-Topline-Results-from-Phase-1-Study-of-CCH-for-the-Treatment-of-Uterine-Fibroids - Statistically significant reduction in collagen content of CCH treated uterine fibroids - Wed, 31 Oct 2018 16:30:00 -0400 http://investors.biospecifics.com/2018-10-31-BioSpecifics-Technologies-Corp-Announces-Positive-Topline-Results-from-Phase-1-Study-of-CCH-for-the-Treatment-of-Uterine-Fibroids BioSpecifics Technologies Corp. to Present at Two Upcoming September Conferences http://investors.biospecifics.com/2018-08-30-BioSpecifics-Technologies-Corp-to-Present-at-Two-Upcoming-September-Conferences Thu, 30 Aug 2018 08:01:00 -0400 http://investors.biospecifics.com/2018-08-30-BioSpecifics-Technologies-Corp-to-Present-at-Two-Upcoming-September-Conferences BioSpecifics Technologies Corp. Reports Second Quarter 2018 Financial Results http://investors.biospecifics.com/2018-08-09-BioSpecifics-Technologies-Corp-Reports-Second-Quarter-2018-Financial-Results - Phase 1 trial of CCH for treatment of Uterine fibroids now fully enrolled - Thu, 09 Aug 2018 08:01:00 -0400 http://investors.biospecifics.com/2018-08-09-BioSpecifics-Technologies-Corp-Reports-Second-Quarter-2018-Financial-Results